Post on 18-Jan-2017
transcript
Olaf Kraus de Camargo@DevPeds
Update on ASD Research
April 25th 2016
1
DisclaimerThis is a biased selection based on my
non-systematic readings, clinical practice and small involvement in some of the
studies without any financial gains
2
First: some definitions!• Statistically Significant: usually means that the chance that an observed effect is related to an
intervention is at least 95% - it does not tell if this effect is big or small!• Clinically Significant: describes how meaningful is the effect• Evidence level: refers to the type of studies done to describe a certain effect and the likelihood that
the results can be trusted.• Randomized: it is a lottery to determine which child gets which treatment• Double-blind: neither patient/caregiver nor experimenter knows who is being treated
3
4
Causes for ASD
Bourgeron, T., 2015. The genetics and neurobiology of ESSENCE: The third Birgit Olsson lecture. Nord. J. Psychiatry 9488, 1–9. doi:10.3109/08039488.2015.1042519
Genetic: 600 -700 candidate genetic alterations
“The recent advances in genomics have demonstrated that an identical genetic variant may increase the risk for a wide range of diagnoses formerly thought of as distinct”
5
ASD & Genes
Bourgeron, T., 2015. The genetics and neurobiology of ESSENCE: The third Birgit Olsson lecture. Nord. J. Psychiatry 9488, 1–9. doi:10.3109/08039488.2015.1042519
6
ASD & Genes &…...
Zhao, Y., Castellanos, F.X., 2016. Annual Research Review: Discovery science strategies in studies of the pathophysiology of child and adolescent psychiatric disorders: promises and limitations. J. Child Psychol. Psychiatry n/a–n/a. doi:10.1111/jcpp.12503
7
ASD & Prematurity
8
ASD & Prematurity
9
International Classification of Functioning, Disability and Health (WHO)
10
Research Domain Criteria (NIH)
Domain Genes Cells Circuits Physiology Behaviour SelfReport Paradigm
Negative Valence Systems
Positive Valence Systems
Cognitive Systems
Systems for Social Processes
Arousal and Regulatory Systems
Environment
Dev
elop
men
t
https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml
Body Functions and Body StructuresActivities and Participation
Environmental Factors
Omega-3-fatty acid supplementation
“To date there is no high quality evidence that omega-3 fatty acids supplementation is effective for improving core and associated symptoms of ASD.”
Two double-blind randomized trials - 37 patients
2011
11
Gluten-free, Casein-free Diet
“Evidence to date on the effectiveness of gfcf-d for children with ASD has been inconclusive due to methodologic limitations. Preliminary data suggest there may be a subgroup of children with ASD who respond to a gfcf-d.”
Many low quality studies, only two double-blind randomized trials
12
Social Groups
“There is some evidence that social skills groups can improve social competence for some children and adolescents with ASD.”
Five randomized controlled studies, only children and adolescents with IQ > 70 (196 participants)
13
Risperidone
“There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term.
For aggression, the difference in scores of 6.49 points on the ABC Irritability subscale (range 0 to 45) may be clinically significant. For conduct problems, the difference in scores of 8.61 points on the NCBRF-CP (range 0 to 48) is likely to be clinically significant.”Eight randomized controlled trials, over 200
patients 14
Melatonin
“Melatonin administration in ASD is associated with improved sleep parameters, better daytime behavior, and minimal side effects.”
Five randomized double-blind studies
15
IBI“We found that children receiving the EIBI treatment performed better than children in the comparison groups after about two years of treatment on tests of adaptive behavior (behaviors that increase independence and the ability to adapt to one’s environment), intelligence, social skills, communication and language, autism symptoms, and quality of life. The evidence supports the use of EIBI for some children with ASD. However, the quality of this evidence is low as only a small number of children were involved in the studies and only one study randomly assigned children to groups.”
One randomized trial, four non-randomized trials, 203 children
16
Joint Attention
17
• Analyzed 16 studies• About 750 children• Different approaches were analyzed
(behavioural and developmental)• No RCT’s
Joint Attention
18
• The results of this meta-analysis provide strong support for explicit joint attention interventions for young children with ASD with most comparisons showing a statistically significant 2/3 standard deviation treatment effect increase for the experimental group compared with the control/comparison group.
• No specific type of approach was superior
Research at Mac & HHS
19
• Riluzole: is a substance that reduces the action of glutamate on synapses in the brain
• Has been proposed in ALS, Alzheimer, Depression, Anxiety
• Has been used in a multi-site trial in adolescents with ASD
• Data collection is finished, Analysis is in progress
Research at Mac & HHS
20
• Tideglusib: is a substance that reduces the action of an enzyme (GSK-3β) identified as modulating pathways and reversing symptoms in animal models of fragile-X and congenital myotonic dystrophy
• Recruitment is ongoing (multi-site trial): 12-17 years old with ASD
• Double-blind, placebo-controlled, randomized study
Research at Mac & HHS
21
Research at Mac & HHS
22
• Why is this important?• Is a meaningful concept for ASD as it focusses on a core symptom (not IQ)
• Better description of level of functioning
• Opens the possibility to compare data from different studies
• Will help to identify what works for which children and what does not work!
23
Conclusion• Different types of lesions and exposures to the
brain can result in similar behavioural manifestations
• Despite decades of high level basic research we still lack effective treatments for the majority of children with ASD
• ASD is an example for a spectrum condition - case-control studies are difficult to replicate – need for better description of study populations
24
Conclusion• Understanding complex systems requires
“explorative science” (Big Data)• Effective treatment of spectrum conditions
requires a personalized approach• Future developments will depend on close
cooperations between basic sciences, clinical research, clinical practice and patients with their families
macautism.ca
25
References1.Bourgeron, T., 2015. The genetics and neurobiology of ESSENCE: The third Birgit Olsson lecture. Nord. J. Psychiatry 9488, 1–9.
doi:10.3109/08039488.2015.10425192.Zhao, Y., Castellanos, F.X., 2016. Annual Research Review: Discovery science strategies in studies of the pathophysiology of child
and adolescent psychiatric disorders: promises and limitations. J. Child Psychol. Psychiatry n/a–n/a. doi:10.1111/jcpp.125033.Kuzniewicz, M.W., Wi, S., Qian, Y., Walsh, E.M., Armstrong, M.A., Croen, L. a., 2014. Prevalence and neonatal factors associated
with autism spectrum disorders in preterm infants. J. Pediatr. 164, 20–25. doi:10.1016/j.jpeds.2013.09.0214.Webb, S.J., 2014. Neonatal factors associated with autism spectrum disorders in infants. Evid. Based. Ment. Health 17, 106–106.
doi:10.1136/eb-2014-1017635.James, S., Montgomery, P., Williams, K., 2011. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD).
Cochrane Database Syst Rev Cd007992. doi:10.1002/14651858.CD007992.pub26.Reichow, B., Barton, E.E., Boyd, B.A., Hume, K., 2012. Early intensive behavioral intervention (EIBI) for young children with autism
spectrum disorders (ASD). Cochrane Database Syst Rev 10, Cd009260. doi:10.1002/14651858.CD009260.pub27.Dosman, C., Adams, D., Wudel, B., Vogels, L., Turner, J., Vohra, S., 2013. Complementary, holistic, and integrative medicine:
autism spectrum disorder and gluten- and casein-free diet. Pediatr Rev 34, e36–41. doi:10.1542/pir.34-10-e368.Reichow, B., Steiner, A.M., Volkmar, F., 2013. Cochrane review: social skills groups for people aged 6 to 21 with autism spectrum
disorders (ASD). Evid Based Child Heal. 8, 266–315. doi:10.1002/ebch.19039.Reichow, B., Barton, E.E., Boyd, B.A., Hume, K., 2012. Early intensive behavioral intervention (EIBI) for young children with autism
spectrum disorders (ASD). Cochrane Database Syst Rev 10, Cd009260. doi:10.1002/14651858.CD009260.pub210.Loy, J.H., Merry, S.N., Hetrick, S.E., Stasiak, K., 2012. Atypical antipsychotics for disruptive behaviour disorders in children and
youths. Cochrane Database Syst Rev 9, Cd008559. doi:10.1002/14651858.CD008559.pub211.Rossignol, D.A., Frye, R.E., 2011. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med
Child Neurol 53, 783–792. doi:10.1111/j.1469-8749.2011.03980.x12.Wainer, A.L., Hepburn, S. & McMahon Griffith, E., 2016. Remembering Parents in Parent-Mediated Early Intervention: An
Approach to Examining Impact on Parents and Families. Autism, March 7(Online), pp.1–13.13.Murza, K.A. et al., 2016. Joint attention interventions for children with autism spectrum disorder: a systematic review and meta-
analysis. International Journal of Language & Communication Disorders, p.n/a–n/a.
Collection of ASD papers: https://www.mendeley.com/groups/8628801/asd/